록웰메디컬(RMTI) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

RMTI

Rockwell Medical Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$7.00

+0.37 ▲ +5.58%

록웰메디컬(RMTI) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$28M

스몰캡

P/E

배당수익률

없음

52주 위치

13%

저점 +43% · 고점 -67%

애널리스트

적극 매수

B-

Fundamental health

vs. 미분류 초소형주· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 36%

밸류에이션

Top 63%

재무 안정

Top 34%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-1.47	Insider Own ⓘ	16.74%	Shs Outstand ⓘ	4.0M	Perf Week ⓘ	11.2%
Market Cap ⓘ	0.03B	Forward P/E ⓘ	-	EPS next Y ⓘ	90.34%	Insider Trans ⓘ	-	Shs Float ⓘ	3.3M	Perf Month ⓘ	7.56%
Enterprise Value ⓘ	0.02B	PEG ⓘ	-	EPS next Q ⓘ	-0.23	Inst Own ⓘ	9.9%	Short Float ⓘ	2.6%	Perf Quarter ⓘ	-19.79%
Income ⓘ	-0.01B	P/S ⓘ	0.41	EPS this Y ⓘ	41.33%	Inst Trans ⓘ	-	Short Ratio ⓘ	2.41	Perf Half Y ⓘ	-39.13%
Sales ⓘ	0.07B	P/B ⓘ	0.77	EPS next 5Y ⓘ	-	ROA ⓘ	-9.7%	Short Interest ⓘ	0.09M	Perf YTD ⓘ	-16.02%
Book/sh ⓘ	9.08	P/C ⓘ	1.16	EPS past 3/5Y ⓘ	56.86% 49.2%	ROE ⓘ	-16.04%	52W High ⓘ	-66.67% ($21.00)	Perf Year ⓘ	-34.58%
Cash/sh ⓘ	6.05	P/FCF ⓘ	15.7	Sales past 3/5Y ⓘ	-1.65% 2.17%	ROIC ⓘ	-11.36%	52W Low ⓘ	43.3% ($4.89)	Perf 3Y ⓘ	-79.1%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-1059.59%	Gross Margin ⓘ	17.06%	Volatility(W/M) ⓘ	5.76% 7%	Perf 5Y ⓘ	-91.16%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.27	Sales Y/Y TTM ⓘ	-30.75%	Oper. Margin ⓘ	-7.11%	ATR (14) ⓘ	0.41	Perf 10Y ⓘ	-99.22%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.43	EPS Q/Q ⓘ	8.33%	Profit Margin ⓘ	-7.98%	RSI (14) ⓘ	63.82	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	3.74	Sales Q/Q ⓘ	-8.34%	SMA20 ⓘ	17.87% ($5.94)	Beta ⓘ	1.59	Target Price ⓘ	$30
Payout ⓘ	-	Debt/Eq ⓘ	0.4	Earnings ⓘ	2026/8/13	SMA50 ⓘ	5.6% ($6.63)	Rel Volume ⓘ	1.79	Prev Close ⓘ	$6.63
Employees ⓘ	157	LT Debt/Eq ⓘ	0.33	EPS/Sales Surpr. ⓘ	-60% -3.44%	SMA200 ⓘ	-21.84% ($8.96)	Avg Volume(3M) ⓘ	0.04M	Price ⓘ	$7
IPO ⓘ	1998/1/27	Option/Short ⓘ	No/Yes			Trades ⓘ	400	Volume ⓘ	63,448	Change ⓘ	5.58%

Quarterly earnings trend SEC filings · USD

23.9

24.3

24.6

24.9

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 - · 순이익 $-2M (YoY -6%)

📊 Rockwell Medical Inc (RMTI) Investment Analysis

What kind of company is Rockwell Medical Inc?

록웰메디컬(RMTI)

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

This is a US specialty pharmaceutical company that develops, manufactures, and supplies hemodialysis products for kidney failure patients. Its flagship products include Triferic, which delivers iron directly during dialysis, along with dialysis concentrates (CitraPure, RenalPure, and SteriLyte). The company supplies dialysis centers worldwide and benefits from a stable revenue structure, with more than 80% of customers maintaining long-term contracts.

Learn more about Rockwell Medical Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5150

Employees157people

IPO1998/01/27

Current Price$7.00 ≈ 9,590원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-16

8월 13일 (목) · 장 시작 전

예상 EPS $-0.23

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS -60.0% 매출 -3.4%

🔔 Earnings release 2026년 3월 26일 (목) · 장 시작 전

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-7.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-8.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

17.1%

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Bottom 36%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-16.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-9.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-11.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.40

✓ Healthy debt

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

3.74

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.43

✓ 우수

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$30.00

현재가 대비 +328.6%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+90.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-105.0%

평균 서프라이즈

2026.05.07

하회

실적 $-0.04 · 예상 $-0.03 -60.0%

2026.03.26

하회

실적 $-0.01 · 예상 $0.02 -150.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth

Above the industry average, both historically and going forward

Margin-Driven Growth EPS is growing while revenue is flat — gains may come from cost cuts, so watch sustainability

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+41.3%

양호

My positionMid-range

Low range Average High range

미분류 초소형주 Median 29.4% · Top 44%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+90.3%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 40.2% · Top 25%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+56.9%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 25.4% · Top 22%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+49.2%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 14.6% · Top 18%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+2.2%

평균

My positionMid-range

Low range Average High range

미분류 초소형주 Median 2.8% · Bottom 49%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-8.3%

평균

My positionMid-range

Low range Average High range

미분류 초소형주 Median -2.6% · Bottom 42%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -160%p below the market

RMTI -91.2% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-159.5%p

Significantly behind the market

vs Health Care (XLV)

-115.7%p

Significantly behind the sector average

1-year basis

vs S&P 500

-50.6%p

Significantly behind the market

vs Health Care (XLV)

-54.3%p

Significantly behind the sector average

Rank among peers

5-year return Upper-Mid (41%) Based on 28 peers

1-year return Upper-Mid (43%) Based on 36 peers

Current position within 52-week range

Low (-43.3%p) High (-66.7%p)

Current price is 43.3% above the 52-week low and 66.7% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-49.5%

Annualized volatility

333.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $7.00 above the midline ($5.43). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

⚡

Current diagnosis · 2026-07-27

Death cross — bearish reversal signal

MACD(1.264) crossed below Signal(1.265). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-07-27

Overbought zone — short-term pullback possible

RSI 89.2 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 75.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.77x

✓ Cheap

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 0.78x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

0.41x

✓ Very cheap

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Top 18% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

15.70x

✓ Cheap

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$30.00 vs. current price +328.6%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership flow is positive

Short interest light 2.6%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

No trading data for Institutions

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 9.9%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 16.7%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 73.4%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

2.6%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days Little change

Short interest days to cover

2.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 4.0M주

Float (tradable shares) 3.3M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding RMTI

ETFs with the highest weightings · 3 total shown

IWC

iShares Micro-Cap ETF

0.01%

$1.4B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
RMTI This Stock	$27.6M	-	0.8 ▲	-16.04% ▲	-	+5.6%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 록웰메디컬(RMTI)?

록웰메디컬(RMTI) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of RMTI?

The market cap of RMTI is approximately $28M, ranking 5,150 within its sector.

What is the 52-week high and low for RMTI?

RMTI has recorded a 52-week high of $21.00 and a low of $4.89.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.